Likewise, treatment of a humanized MM mouse model with the CCR1-specific inhibitor MLN3897, led to increased osteoblast function, decreased osteoclast formation, as well as reduced tumor burden (83). This evidence concerns the gene CCR1 and Miyoshi myopathy.